cancer
therapi
character
throughout
histori
up
down
due
ineffect
treatment
side
effect
also
hope
realiti
complet
remiss
cure
mani
case
within
therapeut
arsen
alongsid
surgeri
case
solid
tumor
antitumor
drug
radiat
treatment
choic
instanc
recent
year
immunotherapi
becom
import
therapeut
altern
first
choic
mani
case
nanotechnolog
recent
arriv
scene
offer
nanostructur
new
therapeut
altern
control
drug
deliveri
combin
imag
treatment
appli
hyperthermia
provid
direct
target
therapi
among
other
therapi
appli
either
alon
combin
compon
antibodi
cancer
peptid
folic
acid
etc
addit
gene
therapi
also
offer
promis
new
method
treatment
present
review
evolut
cancer
treatment
start
chemotherapi
surgeri
radiat
immunotherapi
move
promis
cuttingedg
therapi
gene
therapi
nanomedicin
offer
histor
point
view
cover
arriv
therapi
clinic
practic
market
promis
challeng
present
chemotherapi
surgeri
radiotherapi
common
type
cancer
treatment
avail
nowaday
histori
chemotherapi
began
earli
centuri
use
treat
cancer
began
term
chemotherapi
coin
german
scientist
paul
ehrlich
particular
interest
alkyl
agent
came
term
describ
chemic
treatment
diseas
first
second
world
war
notic
soldier
expos
mustard
ga
experienc
decreas
level
leukocyt
led
use
nitrogen
mustard
first
chemotherapi
agent
treat
lymphoma
treatment
use
gilman
follow
year
alkyl
drug
cyclophosphamid
chlorambucil
synthes
fight
cancer
kilt
farber
design
folat
antagonist
aminopterin
amethopterin
lead
develop
methotrex
achiev
leukemia
remiss
children
elion
hitch
develop
treat
leukemia
heidelberg
develop
drug
solid
tumor
import
chemotherapi
agent
colorect
head
neck
cancer
saw
design
corticosteroid
along
establish
cancer
chemotherapi
nation
servic
center
whose
purpos
test
cancer
drug
time
monotherapi
drug
achiev
brief
respons
type
cancer
first
cancer
cure
chemotherapi
choriocarcinoma
report
main
target
hematolog
cancer
better
treatment
develop
alkaloid
vinca
ibenzmethyzin
procarbazin
appli
leukemia
hodgkin
diseas
advanc
hodgkin
diseas
made
curabl
chemotherapi
use
momp
protocol
combin
nitrogen
mustard
vincristin
methotrex
prednison
mopp
protocol
contain
procarbazin
methotrex
patient
diffus
larg
bcell
lymphoma
treat
therapi
cure
advanc
diffus
larg
bcell
lymphoma
report
use
protocol
cmopp
substitut
cyclophosphamid
nitrogen
mustard
surgeri
radiotherapi
basi
solid
tumor
treatment
led
plateau
curabl
rate
due
uncontrol
micrometastas
promis
public
use
adjuv
chemotherapi
radiotherapi
surgeri
cure
patient
advanc
cancer
breast
cancer
first
type
diseas
posit
result
adjuv
therapi
obtain
also
first
exampl
multimod
treatment
strategi
manuscript
review
evolut
oncolog
treatment
avail
today
togeth
sever
immunotherapeut
approach
nanoscalebas
therapeut
includ
success
drawback
recent
progress
concept
immunotherapi
medicin
incorpor
use
compon
immun
system
includ
antibodi
ab
cytokin
dendrit
cell
treat
variou
ill
cancer
allergi
autoimmun
infecti
diseas
immunotherapi
also
includ
use
vaccin
prevent
allergi
tumor
immunotherapi
add
new
dimens
clinic
practic
offer
much
specif
higher
efficaci
direct
therapi
less
toxic
lower
secondari
effect
better
toler
although
immunotherapi
use
sever
ill
macular
degener
autoimmun
diseas
etc
case
cancer
aim
immunotherapi
kill
tumor
cell
either
directli
indirectli
help
patient
immun
system
destroy
tumor
type
antitumor
immunotherapi
review
focu
use
antibodi
histori
problem
current
applic
antibodi
ab
one
import
defens
mechan
vertebr
anim
produc
b
cell
antigenmedi
activ
undergo
differenti
secretori
plasma
cell
thu
produc
solubl
antibodi
antibodi
highli
specif
recogn
elimin
pathogen
diseas
antigen
deliber
gener
recogn
differ
target
molecul
tumor
marker
bacteria
receptor
cytokin
hormon
etc
thu
ab
use
mani
applic
includ
diagnost
techniqu
research
therapi
infect
tumor
transplant
autoimmun
diseas
antibodi
describ
figur
von
behr
kitasato
antitoxin
appear
serum
anim
immun
inactiv
toxin
toxoid
research
note
protect
could
transfer
anim
use
antisera
thu
begin
known
serum
therapi
treat
infecti
diseas
diphtheria
tetanu
human
soon
sera
element
describ
antibodi
could
direct
toxin
also
larg
varieti
organ
compound
bacteria
protein
chemic
etc
immunotherapi
initi
began
use
antisera
obtain
anim
hors
sheep
contain
among
thing
mixtur
antibodi
activ
differ
b
cell
clone
socal
polyclon
antibodi
pab
felton
bailey
obtain
pure
antibodi
thank
work
porter
edelman
nobel
prize
winner
ab
structur
becam
known
introduct
ab
therapi
research
observ
transfer
defens
temporari
oppos
vaccin
induc
longterm
memori
addit
often
incur
anaphylact
respons
occasion
fatal
greatli
reduc
use
human
therapi
howev
problem
prevent
pab
use
success
diagnost
cancer
techniqu
even
prevent
therapi
antisnak
venom
anttetanu
antirh
gamma
globulin
still
use
clinic
practic
figur
histori
antibodi
von
behr
kitasato
show
possibl
gener
antitoxin
tetan
diphtheria
soon
therapi
antiserum
contain
antitoxin
use
patient
took
sever
year
purifi
antibodi
even
know
structur
milstein
develop
first
monoclon
antibodi
gener
applic
monoclon
antibodi
start
diagnosi
research
therapi
initi
modern
immunolog
first
antitumor
monoclon
antibodi
test
molecular
biolog
techniqu
start
design
chimer
human
antibodi
later
transgen
mice
carri
human
ig
gene
anim
model
use
produc
fulli
human
antibodi
cesar
milstein
georg
nobel
prize
winner
succeed
gener
monoclon
antibodi
mab
fuse
mous
b
cell
b
cell
tumor
myeloma
creat
hybrid
cell
immort
capac
produc
larg
quantiti
singl
monoclon
antibodi
genet
studi
susumu
tonegawa
reveal
basi
vast
divers
antibodi
identifi
process
somat
recombin
immunoglobulin
gene
sinc
public
monoclon
antibodi
techniqu
mous
rat
mab
use
mani
laboratori
thousand
applic
variou
scientif
field
diagnost
techniqu
clinic
food
environment
research
therapi
antitumor
autoimmun
diseas
monoclon
antibodi
help
discoveri
new
molecul
identif
membran
protein
group
cd
concept
cluster
differenti
transcript
factor
viral
plant
bacteri
protein
phosphoryl
compound
involv
death
apoptosi
factor
involv
enzymat
cascad
mani
exampl
use
current
classif
leukemia
world
health
organ
base
presenc
absenc
membran
molecul
recogn
monoclon
antibodi
defin
leucocyt
popul
variou
stage
differenti
one
greatest
achiev
monoclon
antibodi
use
human
therapi
surgeri
chemotherapi
radiotherapi
specif
direct
tumor
cell
may
also
affect
healthi
tissu
antibodi
provid
specif
lower
toxic
open
new
therapeut
possibl
first
evid
potenti
came
patient
suffer
lymphoma
respond
treatment
use
mous
mab
direct
specif
tumor
b
lymphocyt
respons
rapidli
encourag
research
product
potenti
therapeut
ab
howev
clinic
trial
result
reveal
mani
patient
receiv
therapi
develop
immun
respons
direct
therapeut
ab
respons
known
hama
human
antimous
antibodi
hara
human
antirat
antibodi
even
develop
anaphylact
reaction
especi
repeat
administr
high
immunogen
antibodi
due
larg
size
compar
convent
pharmaceut
drug
differ
pattern
glycosyl
murin
human
ab
led
cessat
antibodi
use
therapi
complet
human
mab
need
develop
avoid
immun
reject
product
much
complex
initi
thought
contrast
mous
rat
myeloma
cell
human
myeloma
cell
prove
difficult
adapt
continu
growth
vitro
research
tri
resolv
problem
immort
b
cell
use
epsteinbarr
viru
ebv
fuse
human
b
cell
wellestablish
murin
myeloma
obtain
heterohybridoma
howev
low
product
antibodi
cell
instabl
heteromyeloma
cell
numer
technic
problem
lead
search
altern
method
gener
humanlik
mab
one
method
modif
murin
mab
genet
engin
figur
sever
antibodi
molecul
antibodi
fragment
shown
chimer
mousehuman
antibodi
carri
mous
heavi
light
variabl
domain
yellow
rest
molecul
human
origin
red
case
human
antibodi
hypervari
region
mous
deriv
yellow
possibl
gener
bispecif
antibodi
molecul
use
differ
heavi
light
chain
arm
differ
specif
fab
fragment
antigen
bind
scfv
singl
chain
fragment
variabl
vh
variabl
domain
heavi
chain
chimer
murin
variabl
domain
link
constant
region
human
heavi
light
chain
human
hypervari
region
murin
origin
primat
chimer
structur
human
primat
origin
design
recombin
antibodi
fragment
fv
variabl
fragment
fab
antigen
bind
fragment
scfv
singl
chain
variabl
fragment
minibodi
artifici
polypeptid
structur
base
igv
domain
method
use
last
year
reduc
antigen
maintain
bind
affin
specif
origin
ab
rituximab
chimer
mab
first
mab
approv
fda
antitumor
therapi
howev
year
earlier
sever
mab
conjug
radioact
element
approv
vivo
tumor
detect
everi
year
sinc
sever
mab
approv
therapi
us
europ
half
chimer
human
mab
see
tabl
addit
fulli
engin
antibodi
antibodi
fragment
also
advantag
compar
whole
antibodi
especi
term
rate
solid
tumor
penetr
jainr
determin
intact
igg
molecul
need
hour
move
mm
solid
tumor
wherea
fab
fragment
reach
distanc
hour
express
chimer
human
antibodi
carri
eukaryot
host
mammalian
plant
cell
bacteria
wide
use
organ
product
recombin
antibodi
fragment
howev
despit
numer
advantag
avoid
anim
immun
hybridoma
product
low
cost
easier
product
antibodi
fragment
shorter
circul
halfliv
compar
fullsiz
antibodi
lack
glycosyl
lack
effector
function
due
absenc
fc
region
unless
ad
thu
antibodi
therapi
use
incomplet
antibodi
releg
case
rapid
elimin
antibodi
blood
requir
local
therapi
eg
macular
degener
modifi
version
pegyl
fragment
modif
molecul
link
one
polyethylen
glycol
chain
improv
circul
halflif
glycosyl
fc
region
engin
recent
approach
use
research
overcom
problem
mid
thank
develop
molecular
biolog
techniqu
microinject
manipul
embryon
cell
sever
group
creat
variou
transgen
mice
model
carri
human
ig
gene
figur
introduct
human
ig
loci
mice
carri
use
variou
vector
miniloci
yeast
human
artifici
chromosom
yac
hac
respect
vector
transgen
mice
immun
almost
ag
includ
human
tumor
cell
spleen
use
obtain
hybridoma
follow
convent
protocol
moreov
mice
produc
human
ab
intermediatehigh
affin
introduc
mutat
human
ig
transgen
mechan
somat
hypermut
fulli
human
monoclon
antibodi
show
sever
advantag
human
therapi
includ
low
immunogen
better
interact
human
effector
system
pattern
glycosyl
longer
halflif
human
serum
recent
year
mani
fulli
human
mab
introduc
clinic
trial
approv
regulatori
agenc
tabl
addit
use
transgen
mice
gener
fulli
human
mab
altern
develop
use
immunodefici
mice
receiv
human
hematopoiet
tissu
use
chicken
egg
human
ig
code
gene
insert
embryon
cell
gener
transgen
tobacco
plant
produc
human
mab
moreov
sever
group
work
modif
basic
antibodi
structur
gener
monoval
multispecif
reagent
may
variou
therapeut
properti
even
complet
new
structur
exampl
new
reagent
includ
antibodi
altern
protein
scaffold
base
leucinerich
repeat
molecul
lamprey
variabl
lymphocyt
receptor
vlr
librari
fibronectin
domain
design
ankryin
repeat
protein
darp
novel
antibodi
format
immunogen
stabil
aggreg
problem
care
consid
soon
mab
gener
report
potenti
mab
becam
clear
mani
compani
show
interest
develop
new
reagent
diagnosi
design
new
equip
among
contribut
howev
came
field
human
therapi
pharmaceut
compani
initi
show
much
interest
develop
monoclon
antibodi
although
sever
research
group
show
promis
result
preclin
clinic
studi
reason
reluct
mani
number
pharmaceut
compani
experi
gener
small
compound
chemic
synthes
gener
larg
biolog
molecul
produc
cell
moreov
sophist
equip
cell
cultur
control
condit
full
qualiti
assur
necessari
antibodi
product
percept
pharmaceut
compani
product
mab
go
yield
suffici
profit
compani
prefer
concentr
effort
develop
analogu
wellknown
drug
rather
new
product
time
clinician
opt
trial
use
combin
known
agent
view
took
year
chang
advanc
mab
engin
help
develop
effect
mab
drug
high
specif
improv
potenc
stabil
decreas
immunogen
help
chang
compani
initi
reluct
term
clinic
trial
concern
cost
trial
around
time
expens
today
year
ago
time
requir
preclin
pharmacolog
toxicolog
studi
much
regul
difficulti
conduct
earli
clinic
trial
sinc
new
drug
test
advanc
usual
heavili
pretreat
diseas
unlik
dramat
respons
occur
patient
requir
fetal
calf
serum
cell
hybridoma
cultur
introduc
anoth
problem
mad
cow
diseas
identifi
earli
fda
propos
limit
materi
use
medic
product
order
keep
free
agent
thought
respons
mad
cow
diseas
also
known
bovin
spongiform
encephalopathi
bse
make
necessari
find
altern
enrich
media
without
serum
sinc
mab
enter
clinic
studi
variou
diseas
current
clinic
develop
mab
list
tabl
first
mab
approv
cancer
therapi
rituximab
rituxan
tm
chimer
antibodi
direct
nonhodgkin
lymphoma
sinc
mani
other
reach
market
includ
treatment
breast
cancer
trastuzumab
herceptin
acut
myeloid
leukemia
gemtuzumab
ozogamicin
mylotarg
tm
chronic
lymphocyt
leukemia
alemtuzumab
colorect
tumor
cetuximab
erbitux
tm
sever
type
cancer
bevacizumab
avastin
tm
compani
genentech
inc
amgen
bristolmyerssquibb
imclon
system
trion
pharma
repres
portion
pharmaceut
compani
involv
antibodi
market
relat
cancer
therapi
tabl
new
develop
also
occur
immunoconjug
field
mani
current
explor
pharmaceut
industri
immunoconjug
includ
antibodi
link
cancerkil
agent
drug
cytokin
toxin
radioisotop
object
antibodi
act
transport
cancerkil
agent
concentr
agent
directli
cancer
cell
minim
damag
healthi
cell
although
conjug
antibodi
show
toxic
past
recent
approach
develop
appear
decreas
unwant
side
effect
pharmaceut
compani
develop
immunoconjug
independ
form
partnership
special
player
even
acquir
small
biotech
compani
focus
field
immunoconjug
although
challeng
potenti
immunogen
requir
special
attent
sever
practic
advantag
immunoconjug
singl
antibodi
includ
lower
dosag
may
lead
lower
treatment
cost
fewer
side
effect
reintroduct
antibodi
histor
shown
low
efficaci
isol
possibl
use
bacteria
plant
cell
produc
immunoconjug
rather
use
mammalian
cell
cultur
decreas
cost
complex
larg
number
potenti
combin
antibodiescanc
kill
agent
possibl
advantag
immunoconjug
singl
antibodi
make
crucial
player
new
cancer
therapi
develop
although
mani
research
work
monoclon
antibodi
cancer
close
report
subject
found
pubm
http
wwwncbinlmnihgovpubm
therapeut
mab
market
move
much
slowli
initi
expect
due
mostli
problem
indic
situat
chang
recent
year
mab
largest
class
biolog
therapi
develop
repres
multibillion
dollar
worldwid
market
report
recent
scolnik
mab
current
market
us
sale
growth
rate
compar
less
smallmolecul
drug
oncolog
autoimmun
diseas
success
indic
drug
five
mab
sale
excess
thank
basic
research
research
identifi
new
biomark
could
potenti
target
mab
current
numer
mab
variou
development
stage
expect
mani
avail
clinic
use
near
futur
chemotherapi
radiat
therapi
surgeri
common
type
cancer
treatment
avail
today
recent
treatment
variou
stage
develop
includ
angiogenesi
inhibitor
therapi
biolog
therapi
includ
interferon
interleukin
colonystimul
factor
monoclon
antibodi
vaccin
gene
therapi
nonspecif
immunomodul
agent
bone
marrow
peripher
blood
stem
cell
transplant
laser
therapi
hyperthermia
photodynam
therapi
target
cancer
therapi
last
two
decad
larg
number
nanoscal
nanostructurebas
therapeut
diagnost
agent
develop
cancer
treatment
also
prevent
diagnosi
target
cancer
hyperthermia
photodynam
gene
therapi
cancer
treatment
use
engin
nanomateri
therapi
use
isol
combin
cancer
treatment
therebi
take
advantag
abil
target
tumor
activ
passiv
respond
physic
chemic
stimul
intern
extern
deliv
therapeut
gene
cell
nuclei
main
object
nanomateri
cancer
treatment
deliv
therapeut
moieti
tumor
cell
control
manner
depend
requir
pharmacokinet
minim
side
effect
prevent
drug
resist
nanoscal
nanostructur
materi
may
also
use
diagnosi
detect
prevent
patholog
soon
possibl
ideal
abl
sens
cancer
cell
associ
biomark
compar
convent
therapi
nanoparticl
show
six
clear
advantag
cancer
treatment
andor
diagnosi
synthes
specif
size
surfac
characterist
penetr
tumor
take
advantag
enhanc
permeat
retent
effect
epr
mechan
known
passiv
target
engin
target
tumor
cell
surfac
function
biomolecul
attach
tumorspecif
cell
marker
mechan
known
activ
target
engin
penetr
cell
physiolog
barrier
eg
bloodbrain
barrier
bloodretin
barrier
increas
plasma
halflif
carri
chemotherapeut
drug
usual
highli
hydrophob
protect
therapeut
payload
biolog
degrad
synthes
multifunct
platform
combin
imag
therapeut
applic
theragnost
nanoparticl
exampl
variou
nanostructur
materi
potenti
applic
oncolog
shown
figur
advantag
biocompat
nanomateri
contribut
signific
expans
cancer
treatment
target
therapi
oncolog
predict
reach
billion
euro
global
market
total
market
nanobiotechnolog
product
reach
high
billion
tabl
compil
clinic
approv
nanobas
therapeut
cancer
treatment
diagnosi
mani
nanoscal
nanostructurebas
therapeut
diagnost
agent
current
clinic
trial
variou
stage
develop
zhang
et
al
report
clinic
trial
conduct
nanoparticlebas
therapeut
year
later
ongo
clinic
trial
use
nanoparticl
cancer
mention
bergin
present
clinic
trial
develop
larg
number
commerci
nanobas
therapeut
use
cancer
treatment
also
reflect
exponenti
increas
scientif
public
patent
involv
nanomateri
recent
year
figur
show
evolut
last
decad
number
publish
scientif
paper
issu
patent
involv
nanobas
applic
develop
fight
cancer
number
paper
patent
involv
tradit
form
therapi
chemotherapi
radiat
therapi
surgeri
grew
linearli
last
decad
howev
use
term
nano
cancer
shown
exponenti
growth
past
decad
demonstr
major
focu
nanobas
tool
appli
cancer
treatment
diagnosi
recent
advanc
use
nanoscal
nanostructuredbas
therapeut
agent
cancer
treatment
report
nanoparticl
engin
achiev
cell
target
use
select
moieti
eg
antibodi
fragment
carbohydr
peptid
nucleic
acid
bind
correspond
antigen
cell
surfac
carbohydr
overexpress
receptor
tumor
cell
rapid
cellular
prolifer
cell
also
exploit
coupl
nanoparticl
differ
biolog
agent
folic
acid
rational
coupl
carrier
folic
acid
folat
receptor
overexpress
broad
rang
tumor
cell
type
includ
solid
hematolog
malign
reach
target
cargo
releas
interior
cell
ideal
signal
marker
attach
vector
aid
physician
visual
tumor
vector
may
also
graft
moieti
usual
peg
retard
recognit
reticuloendotheli
system
re
increas
nanoparticl
system
circul
addit
recognit
moieti
carri
drug
signal
element
attach
nanoparticl
numer
author
also
envis
design
vector
addit
function
includ
cellpenetr
moieti
combin
sever
drug
combin
drug
gene
prodrug
becom
drug
upon
biochem
modif
tumor
cell
stimulussensit
agent
extern
trigger
molecul
evalu
therapeut
efficaci
function
ad
vector
better
chanc
reach
target
howev
chanc
detect
re
also
increas
therefor
current
market
nanoparticl
use
passiv
target
activ
target
nanoparticl
still
develop
exampl
activ
target
nanoparticl
review
elsewher
target
nanoparticl
fabric
remain
challeng
due
multipl
step
involv
includ
biomateri
synthesi
assembl
target
ligand
couplinginsert
drug
load
surfac
stabil
final
purif
could
caus
batchtobatch
variat
therefor
qualiti
concern
reason
singlestep
synthesi
target
nanoparticl
selfassembl
prefunction
biomateri
provid
simpl
scalabl
manufactur
strategi
mass
product
also
seriou
concern
continu
synthesi
procedur
therefor
still
sought
use
batch
reactor
synthes
nanoparticl
sever
drawback
usual
appear
includ
heterogen
distribut
reactant
temperatur
reactor
insuffici
mix
variat
physicochem
characterist
product
differ
batch
inher
discontinu
numer
postsynthesi
purif
step
usual
requir
order
overcom
disadvantag
microfluid
reactor
eg
micromechan
micromix
capillari
junction
use
continu
synthesi
nanoparticl
precis
control
reaction
temperatur
resid
time
therebi
render
nanoparticl
narrow
particles
distribut
continu
synthesi
process
usual
prefer
synthes
nanoparticl
larg
scale
eg
laser
pyrolysi
arc
discharg
method
anoth
concern
adapt
respons
immun
system
repeat
applic
nanoparticl
immunolog
memori
creat
primari
respons
specif
nanoparticl
provid
enhanc
respons
secondari
encount
type
nanoparticl
exampl
recognit
pegyl
liposom
antipeg
antibodi
report
occur
day
first
administr
pegliposom
lead
fast
clearanc
circul
final
one
last
major
barrier
achiev
transit
target
nanoparticl
use
clinic
practic
complet
understand
potenti
toxicolog
properti
materi
along
exact
pharmacodynam
pharmacokinet
spite
hurdl
mani
research
group
focus
effort
solv
group
also
direct
effort
toward
design
effici
target
nanoparticl
cancer
treatment
term
structur
morpholog
biocompat
surfac
function
advanc
describ
later
document
novel
target
theragnost
nanoparticl
synthes
bifunction
demonstr
among
perfluorocarbon
nanoemuls
clinic
trial
quain
et
al
coupl
pegyl
gold
nanoparticl
singlechain
variabl
fragment
antibodi
recogn
epiderm
growth
factor
receptor
overexpress
mani
type
malign
human
tumor
demonstr
target
capabl
vector
nude
mice
bear
human
headandneck
tumor
nanoparticl
also
abl
function
tag
spectroscop
detect
surfaceenhanc
raman
spectroscopi
magnet
target
also
use
physic
method
target
visual
tumor
effect
magnet
target
extent
select
nanoparticl
accumul
tumor
rat
harbor
orthotop
analyz
use
magnet
reson
imag
mri
sun
et
al
also
demonstr
target
drug
releas
capabl
iron
oxid
nanoparticl
conjug
drug
methotrex
target
ligand
chlorotoxin
monitor
tumorcel
specif
vivo
use
mri
weng
et
al
demonstr
target
tumor
cell
intern
imag
multifunct
quantum
dotconjug
immunoliposom
vitro
vivo
target
deliveri
system
singl
chain
fv
fragment
attach
end
peg
chain
locat
surfac
liposom
target
via
extracellular
activ
nanocarri
promis
method
achiev
activ
target
use
physiolog
stimuli
present
tumor
environ
trigger
mechan
releas
transport
cargo
nanocarri
tumor
environ
take
advantag
acid
ph
uncontrol
enzym
product
complet
descript
system
report
elsewher
tumor
target
prodrug
becom
activ
reach
tumor
cell
anoth
novel
strategi
avoid
unwant
side
effect
drug
allow
deliveri
larg
dose
drug
follow
approach
dhar
et
al
synthes
pt
iv
encapsul
prostatespecif
membran
antigen
target
nanoparticl
poli
llacticcoglycol
acid
plga
poli
ethylen
glycol
peg
function
control
releas
polym
reduct
interior
tumor
cell
prodrug
becom
cisplatin
crosslink
nuclear
dna
photodynam
therapi
pdt
technolog
use
photosensit
activ
upon
exposur
visibl
near
infrar
nir
light
transfer
energi
molecular
oxygen
therebi
gener
reactiv
oxygen
speci
eg
singlet
oxygen
free
radic
peroxid
subsequ
oxid
lipid
amino
acid
protein
induc
cell
death
complet
review
photosensit
report
elsewher
fdaapprov
photosensit
absorb
visibl
spectral
region
nm
light
penetr
millimet
skin
pdt
therefor
limit
treatment
certain
type
skin
cancer
effect
tumor
yet
appar
pdt
usual
perform
outpati
procedur
may
repeat
use
combin
therapi
surgeri
radiat
chemotherapi
photosensit
suscept
photobleach
light
irradi
therefor
load
within
nanoparticl
avoid
drawback
photosensit
also
highli
hydrophob
nanoparticl
explor
carrier
increas
bioavail
nobl
metal
nanoparticl
proven
use
agent
photodynam
therapi
due
enhanc
absorpt
cross
section
four
five
order
magnitud
larger
offer
convent
photoabsorb
dye
silica
nanoparticl
synthes
nonpolar
core
micel
use
entrap
waterinsolubl
photosensit
anticanc
drug
pyropheophorbid
upon
nir
light
irradi
nanoparticl
embed
hela
cell
gener
singlet
oxygen
result
reduct
percentag
cell
surviv
mani
photosensit
embed
within
inorgan
nanoparticl
pdt
includ
metatetra
hydroxyphenyl
chlorin
mthpc
complet
review
variou
nanoparticulatebas
carrier
pdt
report
elsewher
preclin
studi
determin
ad
translat
valu
pdt
therapi
use
photosensit
load
novel
nanoparticl
prior
use
clinic
set
hyperthermia
anticanc
therapi
consist
heat
tumor
inhibit
prolifer
cancer
cell
aim
destroy
render
sensit
effect
convent
protocol
radiat
chemotherapi
fact
hyperthermia
current
use
adjunct
therapi
radiotherapi
andor
chemotherapi
cell
heat
beyond
normal
temperatur
becom
sensit
convent
therapeut
agent
radiat
chemotherapi
high
temperatur
use
typic
heat
caus
irrepar
damag
result
tumor
cell
death
process
known
thermal
ablat
success
local
thermal
ablat
consist
destroy
entir
tumor
mass
without
damag
adjac
vital
structur
requir
particularli
import
patient
limit
reserv
tissu
function
hyperthermia
treatment
make
use
microwav
ultrasound
radiofrequ
focus
use
local
target
tumor
signific
advantag
thermal
technolog
minim
invas
mild
heat
increas
blood
flow
tumor
allow
chemotherapi
exert
greater
effect
cancer
cell
depress
metabol
activ
target
cell
heat
also
reduc
oxygen
demand
tumor
tumor
tissu
oxygen
increas
make
hyperthermia
one
potent
radiosensit
avail
result
clinic
trial
conduct
qualiti
assur
guidelin
shown
hyperthermia
benefici
treatment
sever
type
solid
tumor
includ
breast
cancer
melanoma
sarcoma
local
advanc
cervic
cancer
report
demonstr
improv
overal
surviv
compar
patient
receiv
radiotherapi
chemotherapi
wide
accept
benefit
hyperthermia
significantli
increas
refin
heat
deliveri
technolog
well
monitor
strategi
ensur
optim
thermal
dose
coverag
result
advanc
local
tumor
control
prolong
overal
surviv
integr
hyperthermia
emerg
imag
technolog
noninvas
mrbase
thermometri
help
unveil
full
potenti
hyperthermia
treat
cancer
nanotechnolog
may
offer
window
opportun
improv
heat
deliveri
exampl
highli
focus
ultrasound
energi
transfer
deep
brain
tumor
may
difficult
achiev
due
skull
electromagnet
barrier
magnet
fluid
hyperthermia
mfh
use
iron
oxid
heat
sourc
due
excel
magnet
properti
good
compat
depend
rout
administr
magnet
mediat
hyperthermia
classifi
two
main
type
arteri
embol
hyperthermia
arteri
suppli
use
deliv
magnet
particl
tumor
tissu
direct
intratumor
inject
hyperthermia
magnet
nanoparticl
hyperthermia
set
show
advantag
abl
achiev
sitespecif
tumor
target
aid
extern
magnet
field
magnet
nanoparticl
also
simultan
trace
use
mri
nanoparticl
select
heat
applic
high
frequenc
altern
magnet
field
magnet
energi
dissip
nanoparticl
brown
relax
induc
heat
produc
cell
death
temperatur
signific
antineoplast
effect
mfh
treatment
initi
observ
anim
model
glioma
prostat
cancer
consequ
phase
ii
clinic
trial
thermotherapi
use
magnet
particl
conduct
treat
prostat
carcinoma
glioblastoma
multiform
demonstr
magnet
hyperthermia
conjunct
reduc
radiat
dose
lead
longer
surviv
follow
diagnosi
first
tumor
recurr
compar
convent
therapi
treatment
recurr
glioblastoma
limit
factor
magnet
hyperthermia
report
includ
patient
discomfort
high
magnet
field
strength
well
irregular
intratumor
heat
distribut
even
upon
direct
intratumor
inject
magnetoliposom
ie
magnet
nanoparticl
encapsul
within
liposom
design
achiev
activ
target
tumor
cell
electrostat
interact
hyperthermia
treatment
activ
strategi
includ
antibodyfunction
magnetoliposom
use
combin
hyperthermia
demonstr
effect
target
cytotox
respons
appli
altern
magnet
field
tumorbear
mous
model
har
therapeut
effect
nanoparticledriven
hyperthermia
like
take
advantag
feasibl
use
vector
load
drug
biolog
agent
trigger
releas
upon
heat
order
increas
tumor
control
diseasefre
surviv
use
magnet
hyperthermia
trigger
drug
releas
also
demonstr
feasibl
combinatori
approach
cancer
treatment
purushotham
et
al
develop
magnet
nanoparticl
coat
thermorespons
polym
polynisopropylacrylamid
pnipam
nanoparticl
simultan
hyperthermia
drug
releas
therapeut
relev
quantiti
doxorubicin
hyperthermia
temperatur
achiev
vitro
vivo
target
doxorubicinload
nanoparticl
inject
directli
via
main
hepat
arteri
hepatocellular
carcinoma
rat
model
follow
mri
examin
nirabsorb
nanoparticl
advantag
abl
absorb
scatter
light
thu
produc
heat
increas
temperatur
tissu
nanoparticl
embed
region
electromagnet
spectrum
notabl
minim
absorpt
water
biolog
chromophor
therefor
nir
light
prefer
trigger
biomed
applic
maxim
penetr
tissu
due
minim
absorb
wavelength
hemoglobin
water
major
absorb
visibl
infrar
light
respect
lowest
absorpt
coeffici
nir
region
around
nm
nir
light
shown
travel
least
cm
breast
tissu
cm
skullbrain
tissu
deep
muscl
use
microwatt
laser
sourc
fda
class
light
higher
power
level
fda
class
shown
penetr
cm
muscl
neonat
skullbrain
use
sio
au
nanoparticl
nanoshel
nirabsorb
tag
also
consid
phototherm
ablat
solid
tumor
pilot
studi
patient
refractori
head
neck
cancer
current
conduct
auau
sulfid
nirabsorb
nanoparticl
nm
provid
higher
absorpt
nanoshel
absorpt
scatter
auau
versu
absorpt
scatter
sio
au
nanoshel
well
potenti
better
tumor
penetr
nanoparticl
use
nir
includ
hollow
gold
nanoparticl
smaller
sio
au
nanoshel
thu
give
prolong
blood
circul
halflif
increas
chanc
reach
tumor
maltzahn
et
al
demonstr
peg
protect
gold
nanorod
exhibit
superior
spectral
bandwidth
higher
phototherm
heat
gener
per
gram
gold
longer
circul
halflif
compar
gold
nanoshel
well
approxim
twofold
higher
xray
absorpt
clinic
iodin
contrast
agent
nirabsorb
nanoparticl
also
function
antibodi
achiev
tumor
target
medulloblastoma
cell
hollow
gold
nanoparticl
load
hormon
analog
potent
agonist
melanocortin
receptor
overexpress
melanoma
demonstr
select
phototherm
ablat
melanoma
nanoshel
load
cell
monocyt
lineag
act
carrier
incorpor
human
breast
tumor
nude
mice
photoinduc
cell
death
nanoparticleload
macrophag
abl
induc
death
malign
cell
tumor
hypox
microenviron
current
studi
focus
engin
effici
nirabsorb
nanomateri
function
target
moieti
compar
current
avail
noninvas
procedur
capabl
increas
temperatur
target
tumor
main
drawback
magnet
nirabsorb
nanoparticl
aris
necessarili
invas
natur
well
rel
indiscrimin
natur
tissu
damag
due
effici
intracellular
uptak
concern
regard
acut
longterm
effect
inorgan
nanoparticl
accumul
cytotox
emerg
biomed
research
commun
despit
increas
number
newli
develop
nanoparticl
design
hyperthermia
applic
number
studi
address
toxic
low
collect
data
indic
size
crystallin
shape
surfac
chemistri
strongli
influenc
mechan
inorgan
nanoparticl
intern
cell
biodistribut
metabol
potenti
toxic
highlight
great
import
increas
understand
healthi
tumor
cell
interact
nanoparticl
expect
ongo
studi
help
reconcil
conflict
data
demonstr
safeti
inorgan
particl
report
transient
acut
vivo
toxic
gene
therapi
aim
treat
diseas
introduc
dna
rna
small
interf
rna
antisens
oligonucleotid
specif
target
cell
tissu
restor
miss
function
erad
pathogen
dysfunct
therapeut
gene
materi
deliv
specif
target
cell
use
effici
vector
aim
sustain
stabl
regul
gene
express
without
creat
unwant
side
effect
viral
carrier
organ
cation
compound
recombin
protein
inorgan
nanoparticl
four
kind
carrier
current
explor
gene
deliveri
applic
show
advantag
disadvantag
none
fulfil
criteria
ideal
vector
inde
virus
regard
nanoparticl
due
dimens
regular
geometri
wellcharacter
surfac
properti
wide
use
viral
vector
gene
transfer
includ
adenovirus
ad
domin
gene
deliveri
system
clinic
set
adenoassoci
virus
herp
virus
retrovirus
lentivirus
virus
effici
carrier
howev
limit
dna
cargo
capac
caus
immunogen
toxic
manufactur
rather
expens
gener
synthet
deliveri
system
prevent
specif
immun
respons
may
carri
higher
amount
materi
without
strict
limit
size
genet
drug
concept
gene
therapi
initi
envis
due
cumbersom
natur
test
requir
design
produc
effect
safe
vector
gene
therapi
system
fulli
develop
earli
first
clinic
trial
approv
numer
vector
carri
variou
therapeut
gene
engin
use
test
preclin
studi
due
simplist
belief
straightforward
success
gene
therapi
mani
viral
vector
rapidli
move
clinic
set
although
success
could
demonstr
earli
clinic
studi
even
conduct
far
perfect
vector
seriou
advers
effect
patient
death
led
rigor
regul
gene
therapi
protocol
human
use
evolut
current
success
cancer
strategi
discuss
section
also
includ
signific
failur
setback
restrain
invest
chemotherapi
immunolog
therapi
howev
pharmaceut
industri
yet
develop
singl
cancer
gene
therapi
product
develop
genet
medicin
left
academ
institut
small
biotechnolog
compani
addit
drawback
clinic
trial
gene
therapi
led
extend
period
sever
cut
public
research
fund
fda
yet
approv
human
gene
therapi
product
sale
although
generel
research
grow
rapidli
mani
clinic
trial
ongo
phase
ii
aim
dose
determin
toxic
assess
due
unknown
safeti
profil
gene
vector
design
approv
human
trial
facilit
lifethreaten
diseas
approxim
trial
conduct
worldwid
sinc
twothird
conceiv
cancer
diseas
due
complex
natur
cancer
numer
gene
therapi
approach
fight
includ
strategi
restor
mutant
suppressor
gene
function
inactiv
oncogen
express
suicid
gene
elicit
protect
immun
respons
oncolyt
virus
also
engin
exploit
tumor
cell
characterist
replic
target
cell
method
improv
dissemin
biolog
agent
solid
tumor
deliveri
therapeut
gene
encod
protein
cytotox
antiangiogen
action
transcript
target
use
regulat
promot
explor
way
restrict
transgen
express
optim
therapeut
window
date
two
gene
therapi
product
avail
market
clinic
use
approv
cancer
treatment
china
sinc
china
countri
world
gene
therapi
licens
practic
product
adenovir
vector
market
brand
name
gendicin
tm
oncorin
tm
gendicin
tm
replicationincompet
ad
treatment
head
neck
squamou
cell
cancer
combin
radiotherapi
oncorin
tm
oncolyt
ad
similar
discontinu
exampl
virus
almost
reach
market
given
cerepro
sitimagen
ceradenovec
adenovir
vector
contain
herp
simplex
viru
thymidin
kinas
gene
cdna
control
cytomegaloviru
promot
manufactur
ark
therapeut
ltd
treatment
highgrad
glioma
oral
ganciclovir
cerepro
demonstr
signific
efficaci
recent
phase
iii
trial
trial
still
requir
approv
order
provid
suffici
level
evid
clinic
benefit
similar
gendicin
tm
advexin
tm
contusugen
ladenovec
develop
introgen
therapeut
inc
replicationimpair
adenovir
vector
carri
tumor
suppressor
gene
control
constitut
viral
promot
numer
human
cancer
abnorm
molecul
associ
pathway
contribut
tumor
resist
varieti
convent
therapeut
preclin
data
demonstr
increas
amount
wildtyp
protein
transduct
advexin
tm
phase
ii
iii
trial
conduct
unresect
recurr
head
neck
squamou
cell
carcinoma
respond
adenoviru
therapi
characterist
profil
either
low
express
mutat
wildtyp
inactiv
upregul
inhibitor
genet
immunotherapi
conceiv
deliv
immun
mediat
effici
safe
approach
also
prevent
need
produc
purifi
larg
amount
recombin
protein
tnferad
tm
develop
genvec
secondgener
adenoviru
vector
contain
delet
harbor
gene
function
control
radiationinduc
promot
tnferad
tm
success
test
multicent
phase
ii
iii
random
control
trial
combin
chemoradi
patient
local
advanc
pancreat
cancer
despit
initi
encourag
result
genvec
stop
phase
iii
trial
march
interim
analysi
could
demonstr
relev
evid
effect
exampl
retrovir
vector
cancer
gene
therapi
current
clinic
trial
advanc
pancreat
metastat
breast
cancer
osteosarcoma
soft
tissu
sarcoma
replicationincompet
collagentarget
vector
encod
domin
neg
mutant
human
cyclin
gene
make
lethal
cancer
cell
impress
result
obtain
phase
ii
clinic
trial
demonstr
unpreced
tumor
control
prolong
surviv
clinic
remiss
latestag
cancer
patient
genom
proteom
technolog
quickli
evolv
detect
specif
molecular
target
patient
tumor
sampl
fulfil
promis
person
treatment
approach
inform
collect
emerg
technolog
help
engin
vector
carri
therapeut
gene
specif
target
specif
individu
tumor
properti
envis
futur
cancer
gene
therapi
use
combin
viral
nonvir
vector
tailor
meet
patientspecif
tumor
characterist
consequ
mani
research
group
focus
effort
gener
synthet
carrier
incorpor
featur
mimic
biolog
mechan
viral
gene
deliveri
ideal
synthet
vector
would
incorpor
polycation
sequenc
condens
nucleic
acid
coat
evad
reticuloendotheli
system
would
exhibit
colloid
stabil
properti
prevent
accumul
lung
capillari
would
contain
specif
targetcel
entri
endosom
escap
nuclear
local
signal
goal
synthet
manufactur
biodegrad
vector
administ
system
reach
micro
metastas
carrier
initi
prepar
polym
lipid
dendrim
first
nonvir
gene
therapi
trial
conduct
patient
advanc
melanoma
receiv
intratumor
inject
dnaliposom
complex
result
demonstr
first
time
safeti
feasibl
cancer
treatment
gene
therapi
protocol
use
nonbiolog
carrier
cation
polym
demonstr
superior
gene
transfer
properti
polym
anion
neutral
charg
physiolog
ph
howev
clinic
trial
conduct
carrier
classifi
safe
nonamin
polym
polyvinyl
pyrrolidon
poli
lacid
coglycol
acid
tm
regist
trademark
vical
incorpor
san
diego
ca
usa
promis
cancer
gene
therapi
product
formul
cation
lipid
system
tm
contain
bicistron
plasmid
encod
human
leukocyt
microglobulin
plasmid
allow
immun
system
recogn
metastat
melanoma
lesion
foreign
incorpor
mhc
class
complex
tumor
direct
inject
demonstr
phase
iii
trial
phase
iii
trial
current
conduct
compar
efficaci
tm
convent
chemotherapi
encourag
result
also
obtain
recent
phase
trial
conduct
women
recurr
chemotherapyresist
ovarian
cancer
assess
safeti
toler
plasmid
carri
human
gene
plasmid
formul
synthet
lipopolym
polyethylen
glycolpolyethyleneiminecholesterol
current
numer
nanostructur
system
develop
test
preclin
studi
exampl
selfassembl
nanoparticl
contain
sirna
carrier
dna
protamin
lipid
includ
polyethylen
glycol
ligand
anisamid
target
cancer
cell
prepar
test
li
et
al
author
demonstr
high
effici
system
deliv
genet
materi
xenograft
tumor
intraven
administr
athym
nude
mice
folat
group
also
link
liposom
sirna
deliveri
result
signific
suppress
xenograft
growth
mice
folatepegpolymer
nanoparticl
also
test
vivo
suicid
gene
therapi
applic
use
ganciclovir
prodrug
pegmodifi
gelatinbas
nanocarri
use
vivo
deliv
plasmid
dna
encod
solubl
form
extracellular
domain
vascular
endotheli
growth
factor
antiangiogen
therapi
upon
intraven
administr
overexpress
therapeut
activ
shown
suppress
xenograft
tumor
growth
nanoparticl
also
offer
abil
monitor
deliveri
genet
materi
tan
et
al
abl
synthes
chitosanbas
nanoparticl
encapsul
quantum
dot
coupl
sirna
demonstr
effici
silenc
transfect
track
final
inorgan
nanoparticl
also
develop
despit
low
synthesi
effici
signific
advantag
low
toxic
easi
function
exampl
magnet
liposom
also
test
magnet
hyperthermia
set
induc
therapeut
express
driven
promot
stressinduc
gene
combin
thermal
gene
therapi
treatment
significantli
arrest
tumor
growth
nude
mice
encourag
refin
type
cancer
gene
therapi
success
test
preclin
studi
two
decad
cancer
gene
therapi
use
biolog
vector
preclin
studi
yield
excel
result
clinic
trial
report
satisfactori
result
term
report
mild
longterm
toxic
howev
real
breakthrough
claim
clinic
therapi
reason
differ
outcom
preclin
clinic
trial
includ
inher
limit
rodent
model
develop
homogen
tumor
aris
clonal
cell
line
tumor
found
clinic
practic
compos
heterogen
cell
type
therapi
describ
section
also
confront
similar
limit
develop
main
player
gene
therapi
vector
transgen
evolv
achiev
highest
possibl
degre
specif
target
cancer
cell
nanotechnolog
alreadi
engin
power
nonbiolog
carrier
varieti
therapeut
gene
demonstr
efficaci
safeti
preclin
test
sinc
current
knowledg
cancer
cell
biolog
far
complet
ongo
futur
clinic
trial
synthet
system
expect
suffer
similar
drawback
term
efficaci
experienc
viral
gene
therapi
system
seen
therapi
alreadi
incorpor
clinic
routin
cancer
treatment
success
cancer
gene
therapi
preced
mani
failur
like
due
greater
extent
technolog
limit
flaw
gener
concept
review
tri
summar
histori
evolut
common
type
cancer
treatment
avail
today
also
new
therapi
studi
last
year
addit
surgeri
chemotherapi
radiat
therapi
hyperthermia
photodynam
therapi
immunotherapi
new
therapi
differ
stage
develop
tri
decreas
drug
toxic
health
tissu
increas
efficaci
target
tumor
angiogenesi
explor
cell
gene
therapi
use
new
nanostructur
diagnosi
therapeut
purpos
nanotechnolog
offer
new
product
either
use
alon
due
intrins
properti
combin
biomolecul
antitumor
drug
folic
acid
albumin
antibodi
aptam
could
use
target
cancer
cell
howev
histori
tell
us
fight
cancer
easi
task
mani
type
cancer
abl
resist
convent
therapi
differ
combin
drug
therapi
eg
surgeri
togeth
radiotherapi
chemotherapi
usual
way
destroy
tumor
cell
may
also
true
new
therapi
arriv
clinic
much
studi
requir
new
way
treatment
open
door
hope
mani
patient
wait
success
therapi
